abstract |
Liquid pharmaceutical compositions providing improved oral bioavailability of compounds that are HIV protease inhibitors are disclosed. In particular, the composition comprises a solution of (a) an HIV protease inhibitor and optionally (b) a surfactant in a pharmaceutically acceptable organic solvent. The composition may optionally be encapsulated in a hard gelatin capsule or a soft elastic capsule (SEC). |